1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. Asia Pacific Chronic Cough Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. Asia Pacific Chronic Cough Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1 Rising Incidences of Chronic Cough
- 5.1.2 Growing Product Developments to Treat Chronic Cough
5.2 Market Opportunities
- 5.2.1 Aging Population is Expected to Drive Demand for Chronic Cough Treatment
5.3 Future Trends
- 5.3.1 Continuous Trend of Drug Development
5.4 Impact of Drivers and Restraints
6. Asia Pacific Chronic Cough Market Regional Analysis
6.1 Asia Pacific Chronic Cough Market Overview
6.2 Asia Pacific Chronic Cough Market Revenue 2017-2027 (US$ Million)
6.3 Asia Pacific Chronic Cough Market Forecast Analysis
7. Asia Pacific Chronic Cough Market Analysis – by Drug Class
7.1 Antihistamines
- 7.1.1 Overview
- 7.1.2 Antihistamines: Asia Pacific Chronic Cough Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Corticosteroids
- 7.2.1 Overview
- 7.2.2 Corticosteroids: Asia Pacific Chronic Cough Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Decongestants
- 7.3.1 Overview
- 7.3.2 Decongestants: Asia Pacific Chronic Cough Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Combination Drug
- 7.4.1 Overview
- 7.4.2 Combination Drug: Asia Pacific Chronic Cough Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Antibiotics
- 7.5.1 Overview
- 7.5.2 Antibiotics: Asia Pacific Chronic Cough Market – Revenue and Forecast to 2031 (US$ Million)
7.6 Acid Blockers
- 7.6.1 Overview
- 7.6.2 Acid Blockers: Asia Pacific Chronic Cough Market – Revenue and Forecast to 2031 (US$ Million)
7.7 Other Drug Class
- 7.7.1 Overview
- 7.7.2 Other Drug Class: Asia Pacific Chronic Cough Market – Revenue and Forecast to 2031 (US$ Million)
8. Asia Pacific Chronic Cough Market Analysis – by Route of Administration
8.1 Oral
- 8.1.1 Overview
- 8.1.2 Oral: Asia Pacific Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
8.2 Injections
- 8.2.1 Overview
- 8.2.2 Injections: Asia Pacific Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
8.3 Nasal
- 8.3.1 Overview
- 8.3.2 Nasal: Asia Pacific Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Other Route of Administration
- 8.4.1 Overview
- 8.4.2 Other Route of Administration: Asia Pacific Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
9. Asia Pacific Chronic Cough Market Analysis – by Distribution Channel
9.1 Hospital Pharmacy
- 9.1.1 Overview
- 9.1.2 Other Route of Administration: Asia Pacific Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
9.2 Online Pharmacy
- 9.2.1 Overview
- 9.2.2 Other Route of Administration: Asia Pacific Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
9.3 Retail Pharmacy
- 9.3.1 Overview
- 9.3.2 Other Route of Administration: Asia Pacific Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
10. Asia Pacific Chronic Cough Market – Asia-Pacific Analysis
10.1 Asia-Pacific
- 10.1.1 Asia Pacific Chronic Cough Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 10.1.1.1 Asia Pacific Chronic Cough Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 China:
Asia Pacific Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.1.1 China: Asia Pacific Chronic Cough Market Breakdown, by Drug Class
- 10.1.1.1.2 China: Asia Pacific Chronic Cough Market Breakdown, by Route of Administration
- 10.1.1.1.3 China: Asia Pacific Chronic Cough Market Breakdown, by Distribution Channel
- 10.1.1.2 India:
Asia Pacific Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.2.1 India: Asia Pacific Chronic Cough Market Breakdown, by Drug Class
- 10.1.1.2.2 India: Asia Pacific Chronic Cough Market Breakdown, by Route of Administration
- 10.1.1.2.3 India: Asia Pacific Chronic Cough Market Breakdown, by Distribution Channel
- 10.1.1.3 Japan:
Asia Pacific Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.3.1 Japan: Asia Pacific Chronic Cough Market Breakdown, by Drug Class
- 10.1.1.3.2 Japan: Asia Pacific Chronic Cough Market Breakdown, by Route of Administration
- 10.1.1.3.3 Japan: Asia Pacific Chronic Cough Market Breakdown, by Distribution Channel
- 10.1.1.4 Australia:
Asia Pacific Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.4.1 Australia: Asia Pacific Chronic Cough Market Breakdown, by Drug Class
- 10.1.1.4.2 Australia: Asia Pacific Chronic Cough Market Breakdown, by Route of Administration
- 10.1.1.4.3 Australia: Asia Pacific Chronic Cough Market Breakdown, by Distribution Channel
- 10.1.1.5 Rest of Asia-Pacific :
Asia Pacific Chronic Cough Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.5.1 Rest of Asia-Pacific : Asia Pacific Chronic Cough Market Breakdown, by Drug Class
- 10.1.1.5.2 Rest of Asia-Pacific : Asia Pacific Chronic Cough Market Breakdown, by Route of Administration
- 10.1.1.5.3 Rest of Asia-Pacific : Asia Pacific Chronic Cough Market Breakdown, by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Asia Pacific Chronic Cough Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 Novartis AG
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Teva Pharmaceutical Industries Ltd
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 GlaxoSmithKline plc.
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Bayer AG
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Mylan N.V.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Amneal Pharmaceuticals, Inc.
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Cipla Inc.
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Reckitt Benckiser Group plc.
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Sun Pharmaceutical Industries Ltd
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Aurobindo Pharma Ltd.
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights